TILL TRANSAKTIONER
Hälsovård

The MEG business of Elekta has been acquired by York Instruments Ltd

We advised Elekta AB on the sale of MEGIN, its MEG business, to York Instruments Ltd. Financial details have not been disclosed.

Magnetoencephalography (MEG) is the brain activity-mapping business of Elekta. MEG is a diagnostic functional neuroimaging technique for mapping brain activity. This can be applied in a clinical setting to find locations of abnormalities as well as in a research setting to simply measure brain activity. Elekta's MEG business, known as MEGIN, is a leading supplier of magnetoencephalography (MEG) technology, with more than 100 delivered MEG systems worldwide.

York Instruments Ltd. is a company specializing in magnetic measurements and their healthcare applications. Using the very latest technologies and methodologies, York Instruments is focused on magnetoencephalography (MEG) and its ability to effectively assess neural networks. York Instruments' revolutionary MEG technology allows for earlier and improved diagnostic capability in relation to a variety of neurological diseases and conditions.

Elekta AB is a Swedish company that provides radiation therapy, radiosurgery, related equipment and clinical management for the treatment of cancer and brain disorders. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm.

Oaklins' team in Finland acted as financial advisor to the seller in this transaction. Oaklins' Dutch team supported the transaction by initially approaching Elekta AB.

Prata med transaktionsteamet

Marcus Blomqvist

Partner
Helsingfors, Finland
Oaklins Finland

Maarten Wolleswinkel

Partner
Amsterdam, Nederländerna
Oaklins Netherlands

Relaterade transaktioner

Bayer AG has entered into a takeover agreement with Cara Care
Hälsovård | TMT

Bayer AG has entered into a takeover agreement with Cara Care

Bayer AG, renowned for its advancements in healthcare and life sciences, has finalized the acquisition of Cara Care (HiDoc Technologies GmbH), which entered debtor-in-possession proceedings in October 2024. Cara Care, an innovative digital health platform and official DiGA, aligns perfectly with Bayer’s strategic focus on digital health and the expansion of its innovative solutions portfolio. The transaction is expected to close in Spring 2025.

Lär dig mer
Vivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.
Hälsovård

Vivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.

NEXXUS-IBERIA SGEIC, S.A. a private equity firm in Spain, has completed its acquisition of a majority stake in Vivo Diagnóstico. With this financial backing from NEXXUS-IBERIA, Vivo will focus on inorganic growth as well as investing in service quality, innovation and efficiency.

Lär dig mer
Creo Medical Group plc has completed a US$15.7 million equity fundraise
Hälsovård

Creo Medical Group plc has completed a US$15.7 million equity fundraise

Creo Medical Group plc, the provider of pioneering endoscopic healthcare solutions to clinicians and healthcare providers across the world, has completed a US$15.7 million (£12.1 million) equity fundraise.

Lär dig mer